This document refers explicitly to the effect of medications, specific clinical disorders and acute stressors on the biochemical interpretation of metadrenalines. Consider this when investigating a patient for phaeochromocytoma and paraganglioma.

Agent	Example	Mechanism	Plasma and Urine metadrenalines		
			NMA	MA	3-MT
Stimulants	Nicotine	Activation of nicotinic cholinergic receptors. Increased adrenal secretion of adrenaline	<b>↑</b>	↑ (	
	Caffeine	Mobilisation of intracellular calcium stores. Increased adrenal secretion of adrenaline			
Sympathomimetics	Amphetamine, methamphetamine	Increased released of monoamines from sympathetic nerves	$\uparrow$	$\uparrow$	
		Inhibition of monoamine oxidase			
		Blockage of neuronal cell membrane transporters			
	Ephedrine.	Activation of $\alpha$ - and $\beta$ -adrenergic receptors	↑ (	1	
	pseudoephedrine	Inhibit noradrenaline reuptake			
		Inhibits function of vesicular monoamine function			
Noradrenaline receptor uptake blockers	Tricyclic antidepressants (e.g. Amitriptyline, clomipramine, dosulepin)	Blockage of neuronal cell noradrenaline membrane transporters	↑↑		
	Venlafaxine, duloxetine	Blockage of neuronal cell noradrenaline membrane transporters			
	Cocaine	Centrally medicated sympathoinhibition	$\uparrow\uparrow$	↑	
Selective serotonin reuptake inhibitors	Citalopram, fluoxetine, sertraline	Inhibition of neuronal uptake of noradrenaline	↑↑		
α-adrenoreceptor blockers	Phenoxybenzamine, mirtazapine	Antagonism of $\alpha_2$ -adrenoreceptors and sympathetic neurones	↑↑		
	Doxazosin	Antagonism of $\alpha$ -adrenoreceptors	[↑]		
β-adrenoreceptor blockers	Atenolol, labetalol, propranolol	Antagonism of β-adrenoreceptors		1	
Monoamine oxidase	Isocarboxazid,	Blockade of deamination of O-methylated catecholamine	$\uparrow \uparrow$	$\uparrow\uparrow$	
inhibitors	phenelzine, moclobamide	metabolites			
Atypical anti- psychotics	Quetiapine, clozapine	Inhibition of dopamiergic, adrenergic and serotoninergic receptors	↑		
	Risperidone	Antagonism of $\alpha 2$ adrenoreceptors	$\uparrow$		
DOPA related	L-DOPA, methyl-dopa	Metabolised by enzymes that also convert catecholamines			$\uparrow \uparrow \uparrow$

January 2025

Calcium channel blockers	Amlodipine, diltiazem	Activation of sympathetic nervous system	1	Ť	
Diet related*	Banana, pineapple, shelled walnuts, potatoes, tomatoes and beans	Increased intake of biogenic amines	¢		<b>↑</b> ↑

**Table 1.** Potential pharmacological effects of prescribed and recreational drugs, and dietary agents on plasma and urine metadrenalines. MA – metadrenaline; MAO – monoamine oxidase; NMA – normetadrenaline; 3-MT – 3-methoxytyramine. **NOTE:** With the exception of phenoxybenzamine, **anti-hypertensives are not considered to cause appreciable false-positive test results for plasma and urine metadrenalines**. \*If suspected diet related increases in metadrenalines are observed suggest overnight fasting for plasma free metadrenalines and dietary restrictions for total urinary fractionated metadrenalines.

It is generally not necessary to modify medication prior to plasma or urine metadrenalines testing. However, the medications in Table 1, where possible should be taken into consideration if positive results are obtained.

NOTE: If false positive results are suspected, suggest repeat sampling under idealised conditions. This includes, collecting plasma sample in a supine position after an overnight fast and at least 30 minutes in a recumbent position. Interfering medications should be withdrawn for at least two weeks if it is safe to do so, and with dietary modifications as required. Plasma samples should be sent to the laboratory on ice for immediate separation and freezing.

In addition to pharmacological effects on the concentration of plasma and urine metadrenalines also consider the impact of clinical disorders (Table 2) and acute physiological stressors (Table 3) which have the potential to cause significant elevations in metadrenalines

Document Agreed by Dr Andrew Davison Version 3.0

Condition	NMA	MA
Ischaemic heart disease	$\uparrow \uparrow$	<b>↑</b>
Cyanotic congenital heart failure	$\uparrow$	
Acute intracerebral haemorrhage	$\uparrow \uparrow$	1
Pseudo-phaeochromocytoma		1
Panic disorder/Anxiety	↑	$\uparrow\uparrow$
Pain		$\uparrow$
Sleep apnoea syndrome	1	
Renal failure	1	
Acrodynia	$\uparrow\uparrow$	1
Factitious catecholamine administration	1	1

**Table 2.** Clinical disorders with the potential to cause false-positive test results of metadrenalines in plasma or urine. MA – metadrenaline; NMA – normetadrenaline.

Acute daily stressor	Precaution
Vigorous exercise	Avoided during 24 h urine collection and for several hours before blood sampling
Seated or upright posture during sampling	Blood should be drawn after at least 20 mins of supine rested
Cold environment	Blood should be drawn after sufficient time to acclimate to warm inside temperatures
Acute emotional stress during venipuncture	For children or adult patients with needle phobia use indwelling canula or suggest 24 h urine collection
Stressful working day	Avoid 24 h urine collection during stressful working days

**Table 3.** Acute stressors associated with false-positive metadrenaline test results.

## References

- 1. Brannan EH, et al. Elemental mercury poisoning presenting as hypertension in a young child Pediatr Emerg Care. 2012;28(8):812-814.
- 2. Carlson JT, et al. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest 1993;103(6):1763-1768.
- 3. Chidakel AR, et al. Utility of plasma free metanephrines in diagnosis of factitious pheochromocytoma. Endocr Pract 2006;12(5):568-571.
- 4. Eisenhofer G et al. Biochemical Assessment of Pheochromocytoma and Paraganglioma. Endocrine Reviews 2023;00:1–48.
- 5. Eisenhofer G, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003;88:2656-66.
- 6. Eisenhofer G, et al. Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine. Ann Clin Biochem 2014;51:38–46.
- 7. Eisenhofer G, et al. Plasma metadrenalines: do they provide useful information about sympatho-adrenal function and catecholamine metabolism? Clin Sci (Lond) 1995;88(5): 533-542.
- 8. Eisenhofer G, et al. Plasma metanephrines in renal failure. Kidney Int 2005;67(2):668-677.
- 9. Hamann GF, et al. Pattern of elevation of urine catecholamines in intracerebral haemorrhage. Acta Neurochir (Wien) 1995;132(1–3):42-47.
- 10. Hasking GJ, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73(4):615-621.
- 11. Jazdarehee A, et al. Pseudo-pheochromocytoma due to obstructive sleep apnea: a case report. Endocrinol Diabetes Metab Case Rep 2022;2022: 21-0100.
- 12. Jensterle M, et al. Comparison of plasma metanephrines in patients with cyanotic and acyanotic congenital heart disease. Endocrine 2022;78(3): 580-586.
- 13. Keiser HR. Surreptitious self-administration of epinephrine resulting in 'pheochromocytoma' JAMA. 1991;266(11):1553-1555
- 14. Neary NM, et al. Drugs and pheochromocytoma--don't be fooled by every elevated metanephrine. New Eng J Med 2011;364:2268-70.
- 15. Peitzsch M, et al. Interference from 3-O-methyldopa with ultra-high performance LC-MS/MS measurements of plasma metanephrines: chromatographic separation remains important. Clin Chem 2015;61:993–996.
- 16. Robertson D, et al. Comparative assessment of stimuli that release neuronal and adrenomedullary catecholamines in man. Circulation 1979;59(4):637-643.
- 17. Schürfeld R, et al. False-positive results for pheochromocytoma associated with norepinephrine reuptake blockade. Endocrine-Related Cancer 2024;31:e230063.
- 18. Sharabi Y, et al. Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. J Hypertens 2007;25(11):2286-2295.
- 19. Wilkinson DJ, et al. Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks. Arch Gen Psychiatry 1998;55(6):511-520.

## Document Agreed by Dr Andrew Davison Version 3.0